Wegovy vs Mounjaro: Long-Term Durability of Response

What the Landmark Trials Actually Show

The best way to compare durability is to look at what happens during treatment, then what happens when treatment stops. Those two windows tell very different stories.

STEP-1: The Wegovy Benchmark

STEP-1 (N=1,961) enrolled adults with a BMI of 30 or above (or 27 with at least one weight-related comorbidity) and no type 2 diabetes. At 68 weeks, semaglutide 2.4 mg produced a mean weight loss of 14.9% vs. 2.4% with placebo (P<0.001). About 86% of participants lost at least 5% of body weight, and 32% lost 20% or more. [1]

These numbers look strong. The complication is what happens when the drug stops.

SURMOUNT-1: The Tirzepatide Benchmark

SURMOUNT-1 (N=2,539) tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly in adults with obesity or overweight plus comorbidity, again excluding type 2 diabetes. At 72 weeks, the 15 mg dose produced a mean weight loss of 20.9%. Nearly 57% of participants on the 15 mg dose lost 20% or more of body weight. [2]

That 6-percentage-point gap in mean loss between the two trials is not a head-to-head figure. Patient populations, trial designs, and run-in protocols differed. But the signal is consistent enough across studies that the 2023 Endocrine Society Clinical Practice Guideline on Obesity noted tirzepatide's "numerically superior" efficacy relative to GLP-1 mono-agonists. [3]

SURMOUNT-5: The First Direct Head-to-Head

SURMOUNT-5 published data in early 2025 comparing tirzepatide directly to semaglutide 2.4 mg in adults with obesity and without diabetes. At 72 weeks, tirzepatide produced 20.2% mean weight loss vs. 13.7% for semaglutide, a difference of 6.5 percentage points (P<0.001). Roughly 32% of tirzepatide participants lost at least 25% of body weight, compared to 16% on semaglutide. [4]

These figures matter for durability because the greater the initial loss, the larger the absolute mass that can be regained before the patient returns to their starting weight.

What Happens When the Drug Stops

Wegovy Withdrawal Data

The STEP-1 extension study followed participants who had completed the 68-week trial. Those who stopped semaglutide regained, on average, about two-thirds of their prior weight loss within 12 months. Body weight returned to within 5% of baseline in a substantial portion of the cohort. Cardiometabolic markers that had improved (blood pressure, HbA1c, lipids) also largely reverted. [5]

The Endocrine Society's 2023 guideline states directly: "Weight regain is expected when anti-obesity medications are discontinued, and most patients will require long-term or indefinite pharmacotherapy to maintain weight loss." [3]

This is not a Wegovy-specific failure. It reflects the biology of the hypothalamic weight set-point, which is defended aggressively by the brain once drug-mediated appetite suppression is removed.

Tirzepatide Withdrawal Data from SURMOUNT-4

SURMOUNT-4 provides the cleanest tirzepatide discontinuation data. After a 36-week open-label run-in on tirzepatide, participants were randomized to continue the drug or switch to placebo. Over the next 52 weeks, those who switched to placebo regained 14% of their body weight while those who continued tirzepatide lost an additional 5.5%. [6]

At the end of the placebo period, continued-drug participants weighed about 19.4% less than baseline; those who stopped weighed about 9.9% less. In absolute terms, people on tirzepatide who started at, say, 250 lbs would be around 201 lbs vs. 225 lbs in the placebo group. That 24-lb difference illustrates why the initial depth of loss provides a buffer.

Side-by-Side Regain Summary

| Metric | Wegovy (semaglutide 2.4 mg) | Mounjaro/Zepbound (tirzepatide 15 mg) | |---|---|---| | Mean weight loss on drug | 14.9% at 68 wks (STEP-1) | 20.9% at 72 wks (SURMOUNT-1) | | Mean weight regain after stopping | ~11-12% of body weight at 1 yr | ~14% at 52 wks post-stop (SURMOUNT-4) | | Net loss remaining after stopping | ~3-5% below baseline | ~9-10% below baseline | | Patients losing ≥20% on drug | 32% | 57% (15 mg dose) |

The table makes the durability advantage of tirzepatide concrete: even though the absolute regain in percentage-of-body-weight terms is similar or slightly larger for tirzepatide stoppers, the net residual benefit is roughly double that of semaglutide stoppers because the starting loss was so much deeper.

Mechanism: Why Tirzepatide Outperforms on Weight

Dual Agonism vs. Single Agonism

Wegovy works solely through GLP-1 receptor agonism. It slows gastric emptying, reduces appetite via hypothalamic GLP-1 receptors, and increases insulin secretion in a glucose-dependent manner. [7]

Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor co-agonism. GIP receptors are expressed in adipose tissue and the central nervous system. Animal and early human data suggest that GIP co-agonism may enhance the appetite-suppressing effects of GLP-1 signaling, reduce the nausea associated with pure GLP-1 agonism at high doses, and improve adipose tissue metabolism directly. [8]

What This Means Clinically

The practical consequence of dual agonism is that tirzepatide can reach effective appetite suppression at doses that produce less nausea than equivalent-efficacy semaglutide doses. In SURMOUNT-1, discontinuation due to adverse events was 6.3% on the 15 mg dose. In STEP-1, it was 7.0% on semaglutide 2.4 mg. Tolerability is roughly comparable, but the weight loss ceiling is higher with tirzepatide. [1, 2]

Cardiovascular and Metabolic Durability

Weight loss drugs are increasingly judged not just by the scale but by what they do to cardiovascular risk.

SELECT Trial (Wegovy)

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% vs. Placebo in adults with established cardiovascular disease but without diabetes, over a median follow-up of 33.3 months (HR 0.80; 95% CI 0.72-0.90; P<0.001). This was the first GLP-1-based obesity drug to show a cardiovascular mortality benefit in a dedicated outcomes trial. [9]

Tirzepatide does not yet have a completed cardiovascular outcomes trial for the obesity indication. SURPASS-CVOT is ongoing. Extrapolating SELECT's benefit to tirzepatide is reasonable from a mechanistic standpoint, but it has not been proven.

Glycemic Durability in Type 2 Diabetes

For patients with type 2 diabetes, SURPASS-2 (N=1,879) compared tirzepatide to semaglutide 1.0 mg (the diabetes dose, not the obesity dose). At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.46 percentage points vs. 1.86 for semaglutide 1.0 mg, and produced 12.4% mean weight loss vs. 6.2% (P<0.001 for both). [10]

These glycemic gains also regress after drug cessation, following the same pattern as weight. Continuous therapy is the only way to sustain both outcomes.

Real-World Durability: What Happens Outside Trials

Adherence and Persistence

Trial populations are more adherent than the general population. Real-world persistence data from US pharmacy claims show that roughly 40-50% of patients who start a GLP-1 agonist for obesity discontinue within 12 months, most commonly due to cost, side effects, or insurance disruption. [11]

Because durability of response depends entirely on duration of exposure, cost-driven non-adherence is arguably the largest practical threat to long-term outcomes for both drugs, not any pharmacological limitation.

Insurance and Access

Wegovy carries FDA approval specifically for chronic weight management. Zepbound (tirzepatide's obesity-specific formulation) received FDA approval in November 2023 and now shares that indication. Mounjaro (the diabetes formulation of tirzepatide) is frequently prescribed off-label for obesity where Zepbound coverage is denied, which creates access inconsistencies that the treating physician should document carefully.

Should You Switch from Wegovy to Mounjaro?

This is the most common clinical question when patients plateau on semaglutide.

Who Is a Reasonable Candidate for Switching

Patients who have been on maximally tolerated semaglutide 2.4 mg for at least 16-20 weeks with less than 5% total body weight loss are typically considered inadequate responders. A 2023 analysis in Obesity (Silver Spring) found that roughly 14% of patients on semaglutide lose less than 5% of body weight, and this subgroup shows consistent benefit from switching to a higher-efficacy agent. [12]

Switching is also reasonable for patients who have plateaued at 10-15% loss but whose clinical targets (e.g., remission of metabolic syndrome, avoidance of bariatric surgery) require 20% or more loss.

How to Switch Practically

There is no mandatory washout period between semaglutide and tirzepatide. The standard approach, supported by pharmacokinetic modeling and used in most real-world practice, is to stop the last semaglutide dose and initiate tirzepatide 2.5 mg the following week, titrating normally. Given that semaglutide's half-life is approximately 7 days, the receptor overlap window is brief. Some clinicians wait two weeks in patients with significant GI side effects on semaglutide to reduce additive nausea risk. [13]

The HealthRX clinical switching framework uses three decision gates:

1. Duration gate: Has the patient been on maximum tolerated semaglutide for at least 16 weeks? If not, optimize the current drug before switching.
2. Response gate: Is total body weight loss below clinical target (typically <10% for metabolic benefit, <20% for bariatric surgery avoidance)? If yes, escalation is indicated.
3. Tolerance gate: Did the patient discontinue semaglutide due to intolerable GI side effects? If yes, start tirzepatide at 2.5 mg with a 2-week gap and titrate slowly.

What to Expect After Switching

A retrospective analysis presented at ObesityWeek 2023 found that patients switched from semaglutide to tirzepatide lost an additional 5-8% of body weight over 6 months post-switch, with the largest gains seen in those who had plateaued rather than those who had never responded. Response in plateauers suggests that the dual GIP/GLP-1 mechanism activates pathways that semaglutide alone had saturated. [14]

Practical Dosing and Titration for Durability

Achieving maximum durability requires reaching and maintaining the highest tolerated dose. Half-measures on dose produce half-measures on duration of benefit.

Semaglutide 2.4 mg Titration

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Dose reductions for GI intolerance are permitted but slow attainment of the target. STEP-1 participants on any dose below 2.4 mg showed proportionally lower weight loss. [1]

Tirzepatide Titration

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5.0 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10.0 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Week 21 onward: 15.0 mg weekly (maximum maintenance)

SURMOUNT-1 showed a clear dose-response: mean weight loss was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. Patients who tolerate 15 mg have meaningfully better durability than those maintained at 5 mg. [2]

Safety Profile Comparison Over Time

Both drugs share a GLP-1-mediated side effect profile dominated by nausea, vomiting, diarrhea, and constipation, mostly early in titration. Neither has demonstrated new or unexpected long-term safety signals in trials extending beyond 72 weeks.

The FDA label for both includes a boxed warning regarding thyroid C-cell tumors, based on rodent carcinogenicity data. No causal link has been established in humans. Pancreatitis risk appears comparable and low for both agents, with incidence near background population rates in clinical trial data. [7, 15]

Gallbladder disease (cholelithiasis and cholecystitis) occurs at modestly elevated rates with rapid weight loss on either drug. STEP-1 reported gallbladder-related events in 2.6% of semaglutide participants vs. 1.2% of placebo participants. [1] SURMOUNT-1 reported similar patterns. Patients should be counseled on this risk at initiation.

The Bottom Line on Durability

Tirzepatide produces deeper initial weight loss than semaglutide 2.4 mg across every controlled study to date, including the first direct head-to-head trial (SURMOUNT-5, 20.2% vs. 13.7% at 72 weeks). After stopping either drug, substantial regain occurs within 12 months. The net post-discontinuation benefit is larger with tirzepatide because the initial loss was larger. For patients who are inadequate responders to semaglutide or who have plateaued, switching to tirzepatide produces additional weight loss of roughly 5-8% over 6 months in real-world cohorts. Both drugs require indefinite use to maintain their effects. Patients who can tolerate and afford tirzepatide 15 mg weekly represent the group with the strongest durability argument in the current evidence base.